The report provides an in-depth assessment of the MS market including disease overview, epidemiology, disease management, competitive assessment, unmet needs, R&D strategies, current and future players, and market outlook.
Multiple sclerosis (MS) is an autoimmune disease principally affecting the central nervous system. It causes nerve sheath demyelination followed by axon damage and paralysis with symptoms including muscle weakness, weak reflexes, tremor, muscle spasm, prolonged double vision, slurred speech, and lack of coordination or unsteady gait. Currently, there is no cure for MS. Most approved treatments address the inflammatory and systemic origins of the disease, but few possess neuroprotective effects, and, as such, have an insufficient impact on the underlying neurologic deterioration caused by MS. The primary goal of treatment with disease modifying therapies (DMTs) is to effectively manage disease activity by reducing the frequency of relapses and delaying the accrual of permanent disability. Of all MS subtypes, the treatment of relapsing-remitting MS remains the primary focus of the currently available DMTs.
Multiple sclerosis (MS) is an autoimmune disease principally affecting the central nervous system. It causes nerve sheath demyelination followed by axon damage and paralysis with symptoms including muscle weakness, weak reflexes, tremor, muscle spasm, prolonged double vision, slurred speech, and lack of coordination or unsteady gait. Currently, there is no cure for MS. Most approved treatments address the inflammatory and systemic origins of the disease, but few possess neuroprotective effects, and, as such, have an insufficient impact on the underlying neurologic deterioration caused by MS. The primary goal of treatment with disease modifying therapies (DMTs) is to effectively manage disease activity by reducing the frequency of relapses and delaying the accrual of permanent disability. Of all MS subtypes, the treatment of relapsing-remitting MS remains the primary focus of the currently available DMTs.
Key Highlights
- Report deliverables include a Word report and an Excel-based forecast model
- Forecast includes the 7 major markets (7MM)
- Forecast covers the period 2020-2030
Scope
- Overview of MS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management
- Annualized MS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in =20 years old patient segments forecast from 2020 to 2030
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MS therapy. The most promising candidates in Phase III and IIb development are profiled
- Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines
- Develop business strategies by understanding the trends shaping and driving the global MS therapeutics market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MS therapeutics market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Multiple Sclerosis: Executive Summary - Updated March 2023, based on events up to Feb 28, 20232 Introduction - Updated March 2023, based on events up to Feb 28, 2023
3 Disease Overview - Updated March 2023, based on events up to Feb 28, 2023
4 Epidemiology - Updated March 2023, based on events up to Feb 28, 2023
5 Disease Management - Updated March 2023, based on events up to Feb 28, 2023
6 Competitive Assessment - Updated March 2023, based on events up to Feb 28, 2023
7 Unmet Needs and Opportunity Assessment - Updated March 2023, based on events up to Feb 28, 2023
8 R&D Strategies - Updated March 2023, based on events up to Feb 28, 2023
9 Pipeline Assessment - Updated March 2023, based on events up to Feb 28, 2023
10 Pipeline Valuation Analysis - Updated March 2023, based on events up to Feb 28, 2023
11 Current and Future Players - Updated March 2023, based on events up to Feb 28, 2023
12 Market Outlook - Updated March 2023, based on events up to Feb 28, 2023
13 Appendix - Updated March 2023, based on events up to Feb 28, 2023
List of Tables
Table 1: MS: Key Metrics in the 7MM
Table 2: Risk factors and comorbid conditions associated with MS
Table 3: Revised 2017 McDonald criteria for the diagnosis of MS
Table 4: Treatment guidelines for MS
Table 5: Top three disease-modifying therapies prescribed for MS, by market, 2018
Table 6: Leading disease-modifying drugs for the treatment of MS, 2023
Table 7: MS market - global drivers and barriers, 2020-30
Table 8: Key events impacting sales for MS in the US, 2020-30
Table 9: MS market - drivers and barriers in the US, 2020-30
Table 10: Key events impacting sales for MS in the 5EU, 2020-30
Table 11: MS market - drivers and barriers in the 5EU, 2020-30
Table 12: Key events impacting sales for MS in Japan, 2020-30
Table 13: MS market - drivers and barriers in Japan, 2020-30
Table 14: High-prescribing physicians (non-KOLs) surveyed, By country
List of Figures
Figure 1: Global sales forecast by country for MS in 2020 and 2030
Figure 2: Analysis of the company portfolio gap in multiple sclerosis during the forecast period
Figure 3: Competitive assessment of the injectable late-stage pipeline agents that the publisher expects to be licensed for the treatment of MS during the forecast period
Figure 4: Competitive assessment of the oral late-stage pipeline agents that the publisher expects to be licensed for the treatment of MS during the forecast period
Figure 5: Accrual of disability in the three subtypes of MS
Figure 6: 7MM, diagnosed incidence of MS (cases per 100,000 population), men and women, all ages, 2020
Figure 7: 7MM, diagnosed prevalence of MS (%), men and women, all ages, 2020
Figure 8: 7MM, sources used and not used to forecast the diagnosed incident cases of MS
Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of MS
Figure 10: 7MM, sources used and not used to forecast the diagnosed prevalent cases of MS by type
Figure 11: 7MM, diagnosed incident cases of MS, N, both sexes, all ages, 2020
Figure 12: 7MM, age-specific diagnosed incident cases of MS, N, both sexes, all ages, 2020
Figure 13: 7MM, sex-specific diagnosed incident cases of MS, N, all ages, 2020
Figure 14: 7MM, diagnosed prevalent cases of MS, N, both sexes, all ages, 2020
Figure 15: 7MM, age-specific diagnosed prevalent cases of MS, N, both sexes, all ages, 2020
Figure 16: 7MM, sex-specific diagnosed prevalent cases of MS, N, all ages, 2020
Figure 17: 7MM, diagnosed prevalent cases of MS by type, N, both sexes, all ages, 2020
Figure 18: Expanded Disability Status Scale (EDSS)
Figure 19: Algorithm for the treatment of MS with disease-modifying therapy (DMT)
Figure 20: Unmet needs and opportunities in MS
Figure 21: Overview of the development pipeline in MS
Figure 22: Key late-stage trials for the promising pipeline agents that the publisher expects to be licensed for MS treatment in the 7MM during the forecast period
Figure 23: Competitive assessment of the injectable pipeline drugs benchmarked against the SOC Ocrevus
Figure 24: Competitive assessment of the oral pipeline drugs benchmarked against the SOC Tecfidera
Figure 25: Analysis of the company portfolio gap in MS during the forecast period
Figure 26: Global (7MM) sales forecast by country for multiple sclerosis in 2020 and 2030
Figure 27: Global (7MM) sales forecast by therapy class for multiple sclerosis in 2020 and 2030
Figure 28: Sales forecast by class for MS in the US in 2020 and 2030
Figure 29: Sales forecast by class for MS in the 5EU in 2020 and 2030
Figure 30: Sales forecast by class for MS in Japan in 2020 and 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science
- Banner Life Sciences LLC
- Bayer
- Biogen GmbH
- Bristol-Myers Squibb
- Clene Nanomedicine Inc
- Elan Pharmaceuticals
- Genentech
- Genzyme
- Genmab GlaxoSmithKline AG
- Immunic Inc
- Janssen
- Mapi Pharma Ltd
- MediciNova Inc
- Merck Serona Ltd
- Novartis AG
- Teva LLC
- Roche
- Sanofi
- TG Therapeutics LLC
